ADENOSINE ANNOUNCES COLLABORATION WITH ORTHO-McNEIL TO DEVELOP NOVEL ORAL DRUGS FOR DIABETES AND ASTHMA

Adenosine Therapeutics has signed a worldwide collaboration and option agreement with Ortho-McNeil Pharmaceutical to further develop A2B adenosine receptor antagonist compounds for the potential treatment of Type II diabetes, asthma and other disorders. This relationship will accelerate the clinical development of certain of our family of Adenosine Receptor antagonists that have the potential to offer new oral treatment options for patients suffering from Type II diabetes and asthma, said Robert Capon, CEO and co-founder of Adenosine Therapeutics.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=40177196d80f7b2c&cat=6dcd932030878143)